Family Medicine
Partner With Us
Advertisement
Conexiant chevron_right Family Medicine chevron_right Non-DRE Urine Test May Help Avoid Biopsies for Detection of Prostate Cancer
From the Journals

Non-DRE Urine Test May Help Avoid Biopsies for Detection of Prostate Cancer

"Non–digital rectal examination (DRE) testing provides a convenient, objective, and highly accurate testing option to reduce the need for imaging and biopsy in men with elevated [prostate-specific antigen]."

Conexiant
article Full Article subject Summary summarize Notecard
  1. The MyProstateScore 2.0 (MPS2) test may effectively identify patients who can safely avoid unnecessary prostate biopsies using urine samples.
  2. The test improved biopsy avoidance compared to prostate-specific antigen (PSA) testing and the Prostate Cancer Prevention Trial risk calculator, particularly in patients considering repeat biopsy.
  3. Three MPS2 models were evaluated: biomarkers alone, biomarkers plus clinical factors, and biomarkers with clinical factors and prostate volume.
  4. MPS2 testing detected a high percentage of grade group ≥ 2 cancers and showed potential for improved risk stratification when combined with clinical factors and prostate volume.
  5. MPS2 testing without digital rectal examination requirement could provide a practical first-line test after PSA to determine the need for invasive procedures while maintaining reliable detection of clinically significant prostate cancer.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.